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A B S T R A C T
Identiﬁcation of novel molecular markers and therapeutic targets may improve survival rates for
patients with ovarian cancer. In the current study, immunohistochemical (IHC) analysis of two human
ovarian tumor tissue arrays showed high staining for GDF15 in a majority of tissues. Exogenous
stimulation of ovarian cancer cell lines with recombinant human GDF15 (rhGDF15) or stable over-
expression of a GDF15 expression plasmid promoted anchorage-independent growth, increased
invasion, and up-regulation of matrix metalloproteinases (MMPs) and vascular endothelial growth
factor (VEGF). MMP inhibition suppressed GDF15-mediated invasion. In addition, IHC analysis of human
ovarian tumor tissue arrays indicated that GDF15 expression correlated signiﬁcantly with high MMP2
and MMP9 expression. Exogenous and endogenous GDF15 over-expression stimulated phosphorylation
of p38, Erk1/2, and Akt. Pharmacologic inhibition of p38, MEK, or PI3K suppressed GDF15-stimulated
growth. Further, proliferation, growth, and invasion of GDF15 stable clones were blocked by rapamycin.
IHC analysis demonstrated signiﬁcant correlation between GDF15 expression and phosphorylation of
mTOR. Finally, knockdown of endogenous GDF15 or neutralization of secreted GDF15 suppressed
invasion and growth of a GDF15-over-expressing ovarian cancer cell line. These data indicate that GDF15
over-expression, which occurred in a majority of human ovarian cancers, promoted rapamycin-sensitive
invasion and growth of ovarian cancer cells. Inhibition of mTOR may be an effective therapeutic strategy
for ovarian cancers that over-express GDF15. Future studies should examine GDF15 as a novel molecular
target for blocking ovarian cancer progression.
 2012 Elsevier Inc. 
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Increased circulating levels of growth differentiation factor 15
(GDF15) have been associated clinically with disease progression
in several solid tumor types [1–5]. Knockdown of GDF15 reduced
growth of brain tumor and breast cancer cell lines or xenograft
models [3,6]. Recently, GDF15 was reported as being over-
expressed in serum samples and tumor lysates collected from
patients with advanced ovarian cancer in contrast to patients with
benign ovarian cysts or healthy control subjects [4,7]. However, the
molecular mechanisms by which GDF15 contributes to ovarian
cancer progression were not addressed, and studies examining
whether GDF15 inhibition suppresses growth or invasion of
ovarian cancer have not yet been reported.* Corresponding author at: Department of Pharmacology, Emory University, Suite
5001, 1510 Clifton Rd., Atlanta, GA 30322, United States. Tel.: +1 404 778 3097;
fax: +1 404 778 5530.
E-mail address: rnahta@emory.edu (R. Nahta).
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Open access under CC BY-NC-ND license.Activation of the PI3K/mTOR signaling pathway has been
documented in a majority of ovarian cancers. In one study, primary
human ovarian tumors and solid metastases showed frequent
phosphorylation of Akt (99% of samples) and mTOR (93% of
samples) [8]. In another study, mTOR was found to be phosphory-
lated in 86% of human clear cell carcinomas and 50% of human
serous adenocarcinomas of the ovary [9]. Activation of PI3K/mTOR
in ovarian cancer correlated with poor prognostic indicators
including advanced stage, histologic grade, and residual mass
[8,10].
In the current study, we tested the hypothesis that GDF15
stimulates growth and invasion of ovarian cancer cells. Our data
suggest that GDF15 stimulates ovarian cancer cell growth and
invasion through mechanisms involving PI3K/mTOR and MAPK
signaling. Importantly, GDF15 over-expression was detected in a
majority of human ovarian tumor tissues in association with high
levels of MMP2, MMP9, and phosphorylated mTOR. Inhibition of
mTOR-MMP signaling using rapamycin or the pan-MMP inhibitor
GM6001 blocked GDF15-mediated invasion. In addition, GDF15
knockdown or neutralization suppressed growth and invasion of
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further pre-clinical investigation of GDF15 as a potential mediator
of ovarian cancer growth and invasion.
2. Materials and methods
2.1. Materials
Recombinant human GDF15 (rhGDF15; R&D Systems, 614
McKinley Place NE, Minneapolis, MN 55413) was dissolved in
4 mM HCl containing 0.1% BSA; the solvent (HCl-BSA) was used as
vehicle control. Pan-MMP inhibitor GM6001 (EMD Millipore, 290
Concord Road, Billerica, MA 01821) was dissolved in DMS0 as a
10 mM stock. LY294002 PI3K inhibitor (EMD Millipore) was
dissolved in DMSO to a ﬁnal concentration of 50 mM. PD0325901
MEK inhibitor (Cayman Chemical, 1180 East Ellsworth Road, Ann
Arbor, MI 48108) was dissolved in DMSO to a ﬁnal concentration of
2 mM. SB203580 p38MAPK inhibitor (Sigma–Aldrich, 3050 Spruce
St., St. Louis, MO 63103) was dissolved in DMSO to a ﬁnal
concentration of 100 mM. Rapamycin mTOR inhibitor (Sigma–
Aldrich) was supplied as a 2.74 mM solution in DMSO. TGF beta
receptor type II inhibitor SB431542 (Sigma–Aldrich) was dissolved
in DMSO as a 10 mM stock.
2.2. Immunohistochemistry (IHC)
IHC was performed on 2 sets of human ovarian tumor tissue
microarrays (TMA) using a standard immunoperoxidase proce-
dure. The ﬁrst TMA consisted of 5 normal and 29 ovarian cancer
tissues (Origene, 9620 Medical Center Dr., Suite 200, Rockville,
MD 20850). The second TMA consisted of 122 ovarian cancer
tissues (representing 61 patients, with two different cores from
each patient, giving a total of 122 ovarian tumor tissues), and 10
non-cancerous ovarian tissues (representing 5 subjects, with two
different tissue sections from each subject) (Biochain Institute,
39600 Eureka Drive, Newark, CA 94560). The tissue sections on
glass slide were deparafﬁnized by heating at 60 8C, followed by
passages through xylene and alcohol grades, and ultimately to
water. Antigen retrieval was performed by boiling the slides in
10 mM citrate buffer, pH 6.0 for 10 minutes (min), followed by
cooling in the same buffer for 30 min. The endogenous peroxidase
was quenched by incubating slides with 0.3% H2O2 in methanol for
15 min. Following washes with water and PBS/TBS, slides were
incubated in 10% swine serum (Dako North America, Inc., 6392 Via
Real, Carpinteria, CA 93013) for 1 hour (h) to eliminate any non-
speciﬁc background staining. Tissue sections were stained for
human GDF15 (3249, dilution 1:100; Cell Signaling Technology,
Inc., 3 Trask Lane, Danvers, MA 01923), MMP2 (37150, dilution
1:500; AbCam, 1 Kendall Square, Suite B2304, Cambridge, MA
02139-1517), MMP9 (3852, dilution 1:500; Cell Signaling), or p-
S2448 mTOR (2976, dilution 1:75; Cell Signaling) overnight at
4 8C. Biotinylated anti-rabbit antibody (Dako) was used as
secondary antibody, and positive staining was detected by
incubation with 3,3-diaminobenzidine solution (DAB+ chromo-
gen; Dako North America, Inc.) with hematoxylin as a counter-
stain. The slides were then washed in water and dehydrated by
passing through alcohol grades and xylene. The slides were
mounted with permanent mounting medium Permount (Fisher
Scientiﬁc, 300 Industry Dr., Pittsburgh, PA 15275). After drying
completely, the slides were viewed under a light microscope and
pictures were taken at 10.
2.3. Cell culture
CaOv3, OvCar3, SKOv3, and Tov21G ovarian cancer cells were
purchased from American Type Culture Collection (10801 UniversityBoulevard, Manassas, VA 20110). Culture conditions were: SKOv3 in
RPMI + 10% FBS; OvCar3 in RPMI + 20% FBS, 1% glutamine, and
0.01 mg/mL bovine insulin; CaOv3 in DMEM + 10% FBS; TOV21G in
45% Medium 199, 45% MCB105, 10% FBS. All media was supple-
mented with 1% penicillin/streptomycin. Stable transfectants were
developed by transfecting empty pCMV vector or GDF15 expression
plasmid (Origene) into SKOv3 using Lipofectamine transfection
reagent. After 24 h, 200 mg/mL G418 was added to cultures to select
for transfectants. GDF15 stable clones and control clones were
isolated and tested by real-time PCR for GDF15 expression
normalized to RPLPO internal control; stable transfection was
veriﬁed by real-time PCR in triplicate cultures per clone at least 3
times with reproducible results.
2.3.1. Lentiviral shRNA infection
Lentiviral shRNA construct for GDF15 or control shRNA in
pLKO.1 vector was purchased from Open Biosystems (RHS4078;
2650 Crescent Dr., Suite 100, Lafayette, CO 80026). Lentiviral
helper plasmids (pCMV-dR8.2 dvpr and pCMV-VSV-G) were
obtained from Addgene (8455 and 8454) (1 Kendall Square, Suite
B7102, Cambridge, MA 02139). Transient lentivirus stocks were
prepared following the manufacturer’s protocol. Brieﬂy,
2.5  106 293 T cells were plated in 10 cm dishes. Cells were co-
transfected with shRNA construct (3 mg) together with 3 mg
pCMV-dR8.2 dvpr and 0.3 mg pCMV-VSV-G helper constructs.
Culture medium containing virus was harvested every 24 h for
72 h, and centrifuged 10,000  g overnight at 4 8C. Concentrated
viral supernatant was collected. Tov21G cells were plated in
normal media and infected with puriﬁed virus for 36 h.
2.3.2. Anchorage-independent growth
Cells were plated in matrigel (BD Biosciences, 2350 Qume Drive,
San Jose, CA 95131) diluted 1:1 (media: matrigel). The matrigel-
cell suspension was allowed to solidify, and then media containing
rhGDF15, vehicle control, and/or various drugs (depending on the
experiment) was added to cells in triplicate cultures. Media,
rhGDF15, and drugs were renewed twice a week for 3–4 weeks.
Photographs were taken with an Olympus IX50 inverted micro-
scope at 4 magniﬁcation. Matrigel was digested using dispase
(BD Biosciences), and viable cells were counted by trypan blue
exclusion. Average cell viability of triplicates and standard
deviation between triplicates was calculated. Experiments were
performed twice with reproducible results.
2.3.3. Invasion chamber assays
SKOv3 parental, stable clone, stable GDF15-expressing cells
(5  104 cells/mL), or TOV21G (1  105 cells/mL) were plated in
serum-free media in BD Biosciences BioCoat Matrigel Invasion
Chambers with 0.75 mL of chemoattractant, which was culture
media containing 10% FBS  20 ng/mL rhGDF15. Depending on
the experiment, vehicle control, rapamycin (100 nM), control
human IgG or GDF15 mAb (1 mg/mL) were added directly to
chambers. After 24 h, non-invading cells were removed from the
interior surface of the membrane by scrubbing gently with dry
cotton tipped swab. Each insert was then transferred into 100%
methanol for 2 min followed by H&E staining. The chambers were
incubated with hematoxylin for 6 min followed by acid alcohol and
bluing agent to stain nuclei. Further the slides were incubated in
eosin to stain cytoplasm for 2 min. The slides were then washed in
water and dehydrated by passing through alcohol grades. The
slides were mounted with Permount. Photographs were taken of 10
ﬁelds at 20 magniﬁcation per sample, with triplicates performed
per treatment group. The number of cells was counted in each
ﬁeld; the sum total of the 10 ﬁelds was calculated for each sample.
Experiments were performed at least twice with reproducible
results.
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Cell growth was monitored in real time using a Real-Time Cell
Analyzer Dual-Plate (RTCA DP) instrument (Roche Applied Science,
P.O. Box 50414, 9115 Hague Road, Indianapolis, IN 46250-0414),
placed in a humidiﬁed incubator maintained at a 5% CO2 and 37 8C.
The RTCA DP system records cell index (CI) as a unit-less number
that is a function of electrical impedance of cells attached to
interdigitated electrodes built into the bottom of wells of a 16-well
E-plate (Roche Applied Science). Recording of CI as well as
subsequent data analysis were performed using the RTCA Software
1.2 (Roche Applied Science). Background impedance in each well in
the presence of media alone was measured prior to cell seeding and
automatically subtracted by the RTCA software. For anchorage-
dependent proliferation assays, 5000 cells/well were seeded in E-
plates with 10% FBS containing medium, plus 20 ng/mL rhGDF15
where indicated. CI was recorded every 15 min for 24 h. Assays
were performed at least twice with reproducible results. Cell
migration was assessed using double-chamber 16-well plates with
microelectrodes located on the underside of the upper chamber’s
PET membrane containing 8.1 m pores (CIM-plate 16, Roche
Applied Science). Medium containing 10% FBS was added to the
lower chamber, with 20 ng/mL rhGDF15 where indicated, and cells
were seeded in the upper chamber at 30,000 cells/well in medium
containing 5% FBS with 100 nM rapamycin where indicated. The
CIM-plate 16 was monitored every 15 min for the next 10 h. Assays
were performed at least twice with reproducible results.
2.4. Real-time PCR
Total RNA was extracted using the RNeasy puriﬁcation kit
(Qiagen, 27220 Turnberry Lane, Valencia, CA 91355) and DNase
treated (Invitrogen). cDNA was then prepared from total RNA usingFig. 1. IHC for GDF15 on two human ovarian tumor tissue arrays. (A) A tumor tissue array
was stained for GDF15. Photos were taken at 10 magniﬁcation under the microscope, 
tissue array consisting of 122 tumor tissues and 10 non-cancerous ovarian tissues wa
endometrioid ovarian tumor subtype samples. Photos were taken at 5 magniﬁcation un
for each cancer subtype.random primers and the Superscript III ﬁrst strand synthesis Kit
(Invitrogen). Relative levels of mRNA were determined by real-time
quantitative PCR using an Eppendorf cycler and the TaqMan
Universal PCR master Mix (4304437, Applied Biosystems,
5791 Van Allen Way, P.O. Box 6482, Carlsbad, CA 92008);
RPLPO mRNA levels were used for normalization. Primers
for GDF15 (Hs00171132_m1), MMP-2 (Hs-01548725_m1),
MMP-9 (Hs00957555_m1), VEGF (Hs00153458_m1), and RPLPO
(Hs99999902_m1) were obtained from Applied Biosystems (Taq-
Man Gene Expression Assays). Samples were normalized against the
RPLPO internal control and compared as arbitrary units, represented
as mean  SD. Samples were run in triplicate, and experiments were
repeated at least 3 times with reproducible results.
2.5. ELISA
Human GDF15 immunoassay (R&D Systems) was used according
to the manufacturer’s directions. Brieﬂy, sample media was
incubated in GDF15 antibody-coated microplates for 2 h, then
washed and incubated with GDF15 antibody conjugated to
horseradish peroxidase for 1 h. After washing, plates were incubated
with color reagent (hydrogen peroxide–chromogen mix) for 30 min.
Optical density of each well was determined using a microplate
reader set to 450 nm. The concentrations were calculated according
to the standards supplied with the kit by creating a four parameter
logistic curve-ﬁt. Samples were run in triplicate, and experiments
were repeated 3 times with reproducible results.
2.6. Western blotting
Cells were lysed in RIPA buffer (Cell Signaling) supplemented
with protease and phosphatase inhibitors (Sigma). Total protein consisting of 29 tumor tissue samples and 5 non-cancerous ovarian tissue samples
and representative photos of 2 normal and 2 tumor tissues are shown. (B) A tumor
s stained for GDF15. This second array included 47 serous, 24 mucinous, and 51
der the microscope, and representative photos of positive GDF15 staining are shown
Table 1
IHC analysis of GDF15 on ﬁrst ovarian tumor tissue array.
GDF15 status
Negative
(1.0)
Positive
(>1.0)
N % N %
Non-cancerous tissues (n = 5) 5 100 0 0
Ovarian cancer tissues (n = 29) 8 27.6 21 72.4
21 of 29 ovarian tumor tissues (72.4%) showed positive GDF15 expression, while
none of the 5 non-cancerous tissue samples showed GDF15 staining.
Table 2
IHC analysis of GDF15 according to ovarian tumor subtype on a second array.
GDF15 status
Negative (1.0) Positive (>1.0)
N % N %
Serous (n = 47) 2 4.25 45 95.74
Mucinous (n = 24) 9 37.5 15 62.5
Endometrioid (n = 51) 10 19.6 41 80.39
For all subtypes, a majority of tumors showed positive GDF15 staining. In particular,
the serous subtype showed the highest percentage (95.74%) of tumors with positive
GDF15 staining. Collectively, 101 out of 122 (82.79%) ovarian tumor tissues stained
positive for GDF15.
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Blots were probed overnight using the following antibodies: from
Cell Signaling, monoclonal p-S473 Akt-XP (1:1000), and polyclonal
antibodies against: total Akt (1:1000), p-Thr202/Tyr204 p42/p44
Erk1/2 (1:1000), total p42/p44 Erk1/2 (1:1000), p-Thr180/Tyr182
p38 XP (1:1000), p-Thr 37/46 4EBP1 (1:1000), total 4EBP1
(1:1000), N-Cadherin (1:1000). In addition, polyclonal p38
(1:1000) from EMD Biosciences and b-actin monoclonal AC-15
(Sigma) at 1:10,000. Protein bands were detected using the
Odyssey Imaging System (Li-Cor Biosciences, 4647 Superior Street,
Lincoln, NE 68504-1357). Quantiﬁcation of bands was determined
using ImageJ software.
2.7. Statistics
p-Values were determined for experimental versus control
treatments by two-tailed Student’s t-test, *p < 0.05, **p < 0.005.
IHC staining correlations were determined by two-tailed Fisher’s
exact test.
3. Results
3.1. GDF15 is over-expressed in a majority of human ovarian tumor
tissues
Elevated expression of GDF15 was previously reported in serum
and tumor samples of patients with ovarian cancer [4,7]. To obtain
further evidence that GDF15 expression is increased in ovarian
cancer, we performed IHC on two commercially available human
ovarian tumor tissue arrays (Fig. 1). On the ﬁrst tumor array, 21 of
29 (72.4%) tumor tissues showed GDF15-positive staining, as
compared to 5 non-cancerous tissue samples, none of which
stained positive for GDF15 (Table 1). On the second array, 101 of
122 (82.79%) tumor tissues showed GDF15-positive staining (Table
2), with the most common subtype of ovarian cancer, the serous
subtype, showing over-expression of GDF15 in the vast majority of
samples (45 of 47, or 95.7%). Endometrioid and mucinous subtypes
also showed elevated GDF15 expression in the majority of cases,
with 80.4% and 62.5%, respectively, showing high GDF15 staining.
Thus, GDF15 was over-expressed in the vast majority of ovarian
cancer tissues on two different arrays.
3.2. GDF15 stimulates anchorage-independent growth of ovarian
cancer cells
Since the majority of ovarian tumor tissues expressed GDF15,
we examined the biological effects of increasing GDF15 expression
in ovarian cancer cell lines. SKOv3, OvCar3, and CaOv3 ovarian
cancer cell lines secrete relatively low levels of GDF15 (Fig. 2A), so
we used these lines to examine biological effects of exogenous
stimulation with recombinant human GDF15 (rhGDF15). Cells
were grown in three-dimensional cultures supplemented with
20 ng/mL of rhGDF15, a physiologically relevant concentrationfound in the serum of patients with ovarian cancer [4]. Exposure to
rhGDF15 caused a statistically signiﬁcant increase in anchorage-
independent growth of ovarian cancer cells (Fig. 2B). Cells that
were grown in rhGDF15 showed projections in contrast to control
cultures, suggestive of increased invasiveness. In addition to
stimulating with recombinant cytokine, we stably transfected a
GDF15 expression plasmid into SKOv3 cells (Fig. 2C). GDF15 stable
transfectants showed increased growth in matrigel relative to
control clones (Fig. 2D). Real time cell analysis, which has tight
reproducibility with traditional MTS and trypan blue assays [11–
13], but allows the additional advantage of monitoring growth,
proliferation, or migration in real time over a selected period rather
than at one time point, was used here to obtain additional
conﬁrmation of the growth-promoting effects of GDF15 in ovarian
cancer cells. Cell count proﬁles (the number of cells over time)
were determined for SKOv3 parental cells stimulated with vehicle
control or rhGDF15, and for stable empty vector control and stable
GDF15-transfected clones over a 24 h period (Fig. 2E). GDF15
stable clones showed an increased number of cells relative to
control stable or parental cells, and rhGDF15-stimulated cells
showed an increased number of cells versus vehicle control-
stimulated parental cells. Collectively, the matrigel growth and
real time cell assays demonstrated that GDF15 stimulates growth
and an increase in the number of ovarian cancer cells over time.
3.3. GDF15 increases invasiveness of ovarian cancer cells
Next, SKOv3 cells were plated in matrigel-coated Boyden
chambers, and stimulated with vehicle control or rhGDF15.
Exposure to rhGDF15 caused a dramatic increase in invasiveness
of SKOv3 cells (Fig. 3A). Similarly, GDF15-over-expressing stable
clones showed a signiﬁcant increase in invasiveness through
Boyden chambers compared to control clone cells (Fig. 3B).
Increased invasiveness of cancer cells is often associated with an
epithelial to mesenchymal transition (EMT). GDF15 stable clones
showed morphologic changes representative of transition to a
mesenchymal phenotype (Fig. 3C). GDF15 stable clones showed a
more elongated appearance relative to the control clone, which
showed a more cuboidal phenotype. Western blotting further
suggested EMT in GDF15 stable clones, as the mesenchymal
marker N-cadherin was markedly up-regulated in the presence of
stable over-expression of GDF15. In addition to invasion through
Boyden chambers, we examined cell migration through a
polyethylene terephtalate (PET) membrane using real time cell
analysis XCelligence assay. Consistent with matrigel invasion
assays, stimulation with rhGDF15 or stable over-expression of
GDF15 led to increased migration of ovarian cancer cells in real
time assays (Fig. 3D).
MMP2, MMP9, and VEGF have previously been reported to
mediate ovarian cancer cell invasion [14–16]. Real-time PCR
showed increased expression of MMP2, MMP9, and VEGF in GDF15
stable clones relative to control clone cells (Fig. 3E). In addition, IHC
Fig. 2. GDF15 promotes anchorage-independent growth of ovarian cancer cells. (A) CaOv3, OvCar3, and SKOv3 cells were incubated in serum-free media for 48 h. GDF15
concentration was then determined by ELISA in media from cell lines. (B) SKOv3, OvCar3, and CaOv3 ovarian cancer cells were plated in matrigel, and maintained in media
containing 20 ng/mL rhGDF15 or vehicle control. Media was changed twice a week for 3–4 weeks. Representative photographs taken with 4 objective lens are shown.
Matrigel was dissolved using dispase and cells were counted by trypan blue exclusion. Average fold change in anchorage-independent (AI) cell growth is shown for rhGDF15
group (GDF) versus control vehicle group (C) per line. (C) SKOv3 cells were stably transfected with empty vector control or GDF15 expression plasmid. Three GDF15 stable
clones (G1, G3, G5) were selected and analyzed by real-time PCR for GDF15 transcript level versus control clone (C). Levels of GDF15 transcript were normalized to RPLPO
internal control transcript. Values reﬂect the average fold change in normalized GDF15 transcript expression per stable clone relative to control clone. (D) Control clone (C)
and two GDF15 stable clones (G3 and G5) were plated in matrigel. Media was changed twice a week for 3–4 weeks. Matrigel was then dissolved using dispase and cells were
counted by trypan blue exclusion. Average fold change in anchorage-independent (AI) growth is shown for the GDF15 clones relative to control clone. (E) Growth of SKOv3
parental cells treated with vehicle control or 20 ng/mL rhGDF15, or stable control clone or GDF15 clones G1 or G3 was assessed by Real-Time Cell Analysis. Cell index reﬂects
growth over 24 h, and represents the average of triplicate cultures per group.
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MMP2 and MMP9 in a majority of tumor tissues (Fig. 3F). GDF15
expression was signiﬁcantly correlated with expression of MMP2
and MMP9 (Table 3), supporting the concept that GDF15 over-
expression is associated with increased expression of mediators
of invasion. To determine if increased expression of MMPscontributes to GDF15-stimulated ovarian cancer cell invasion,
we treated GDF15 stable clones with the pan-MMP inhibitor
GM6001. Pharmacologic inhibition of MMPs suppressed invasive-
ness of GDF15-over-expressing cells (Fig. 3G). These results
indicate that GDF15 stimulates ovarian cancer cell invasion
through a mechanism involving MMPs.
Fig. 3. GDF15 promotes invasiveness of ovarian cancer cells. (A) SKOv3 cells were plated in Boyden chambers in the presence of 10% FBS plus vehicle control (C) or 20 ng/mL
rhGDF15. (B) SKOv3 stable control clone, GDF15 stable clone 1, and GDF15 stable clone 3 cells were plated in Boyden invasion chambers in the presence of 10% FBS. For both
(A) and (B), photos were taken after 24 h of invasion, and the number of invaded cells was counted in ten different ﬁelds per sample. Representative photos are shown. Values
reﬂect the total number of invaded cells in triplicate cultures per group. (C) Representative photos of stable control and GDF15 clones are shown at 10 magniﬁcation.
Western blotting for mesenchymal marker N-cadherin was performed twice; a representative blot is shown for total cell lysates from control and GDF15 stable clones.
Quantiﬁcation of N-cadherin was normalized to actin, and is shown relative to control clone. (D) SKOv3, SKOv3 stable control clone, GDF15 stable clone 1, and GDF15 stable
clone 3 cells were plated in the presence of 5% FBS in the upper chamber of XCelligence CIM-plates. Medium containing 10% FBS, and 20 ng/mL rhGDF15 where indicated, was
placed into the plate’s corresponding bottom chambers. Cell index reﬂects cell migration measured every 15 min for 10 h, and represents the average of triplicate cultures per
group. (E) Real-time PCR was performed for invasion markers MMP-2, MMP-9, and VEGF in SKOv3 control and GDF15 stable clones 1, 3, and 5. Values reﬂect the fold change in
transcript normalized to RPLPO housekeeping gene. (F) A tumor tissue array consisting of 122 tumor samples and 10 normal tissue samples was stained for MMP2 and MMP9.
Photos were taken at 5 magniﬁcation under the microscope, and representative photos are shown. (G) SKOv3 control and GDF15 clones were plated in Boyden chambers,
and treated for 24 h with DMSO (C), 1 mM (labeled ‘‘1’’) or 10 mM (labeled ‘‘10’’) of the pan-MMP inhibitor GM6001. The number of invaded cells was counted in ten different
ﬁelds per sample. Values reﬂect the average number of invaded cells in triplicate cultures per group.
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Table 3
IHC analysis of MMP2 and MMP9 and correlation with GDF15 expression.
GDF15 MMP2 MMP9
Neg (1.5) Pos (>1.5) Neg (1.0) Pos (>1.0)
N % N % N % N %
Negative (1.0) (n = 30) 7 23.3 23 76.7 13 43.3 17 56.7
Positive (>1.0) (n = 108) 8 7.4 100 92.6 6 5.6 102 94.4
123 of 138 (89.13%) of ovarian tumor tissues showed positive MMP2 staining, and 119 of 138 (86.23%) of ovarian tumor tissues showed positive MMP9 staining. GDF15 and
MMP2 were signiﬁcantly correlated (p = 0.0209, Fisher’s exact), and GDF15 and MMP9 were signiﬁcantly correlated (p = 0.0001, Fisher’s exact).
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ovarian cancer cells
Based on reports that PI3K activation contributes to ovarian
cancer progression, we performed Western blotting for PI3K and
MAPK signaling molecules in cells stimulated with rhGDF15. These
blots indicated that rhGDF15 induced phosphorylation of
p38MAPK, Erk1/2, and Akt within 2 min of stimulation in SKOv3
and CaOv3 cells (Fig. 4A). To determine if activation of these
signaling pathways is required for GDF15-mediated growth,
ovarian cancer cells were stimulated with rhGDF15 in the presence
of pharmacological inhibitors of PI3K (LY294002), p38 (SB203580),
or MEK (PD0325901). The increase in anchorage-independent
growth that was stimulated by rhGDF15 was overcome by each of
the kinase inhibitors (Fig. 4B). These results suggest that PI3K and
MAPK activation contribute to GDF15-stimulated growth of
ovarian cancer cells.
3.5. Inhibition of mTOR suppresses proliferation and growth of GDF15
stable clones
Next, we examined PI3K and MAPK signaling in stable GDF15-
over-expressing clones. Stable clones showed increased phos-
phorylation of p38, Akt, and 4EBP1 with slight variability between
individual clones (Fig. 4C). To determine if mTORc1 signaling is
important for GDF15-mediated biological effects in ovarian cancer,
we treated GDF15 stable clones with the mTORc1 inhibitor
rapamycin. Stable GDF15 clones showed dose-dependent inhibi-
tion of proliferation in response to rapamycin in contrast to control
cells (Fig. 4D). This increased sensitivity to rapamycin suggests that
GDF15-over-expressing ovarian cancer stable clones may have
acquired dependence upon mTORc1 signaling. Since GDF15 is
structurally related to TGF beta, we also treated stable GDF15
clones with the TGF beta receptor type II inhibitor SB431542. In
contrast to rapamycin, TGF beta receptor inhibition did not affect
proliferation of GDF15 stable clones, suggesting that proliferation
of GDF15 clones is not dependent upon TGF beta signaling.
Consistent with these ﬁndings, GDF15-mediated anchorage-
independent growth of ovarian cancer cells was blocked by mTOR
inhibitor rapamycin, but not by TGF beta receptor inhibitor
SB431542 (Fig. 4E). Finally, since inhibition of PI3K, MEK, and
p38MAPK reduced GDF15-stimulated anchorage-independent
growth of ovarian cancer cells (Fig. 4B), we examined whether
inhibitors of these pathways also reduced anchorage-dependent
proliferation of GDF15 stable clones. In contrast to mTOR
inhibition, clones did not show increased sensitivity to pharmaco-
logical inhibition of PI3K (LY294002), MEK (PD0325901), or
p38MAPK (SB203580) relative to empty vector control (Fig. 4F).
3.6. Inhibition of mTOR suppresses GDF15-mediated invasion in
ovarian cancer cells
Since GDF15 clones showed heightened sensitivity to
rapamycin in MTS assays, we performed Boyden chamberassays to determine if rapamycin also inhibits GDF15-mediated
invasion. The increased invasiveness of SKOv3 cells that was
stimulated by rhGDF15 was suppressed by rapamycin (Fig. 5A).
Rapamycin also reduced rhGDF15-stimulated expression of the
invasion markers MMP9 and VEGF (Fig. 5B). Similarly, invasive-
ness of GDF15 stable clones through matrigel-coated Boyden
chambers was signiﬁcantly reduced by rapamycin (Fig. 5C).
Consistent with these results, real time cell analysis indicated
that migration of GDF15-over-expressing stable clones and
rhGDF15-stimulated SKOv3 cells was inhibited by rapamycin
(Fig. 5D). Finally, to determine if mTOR signaling and GDF15 are
associated in human tumor samples, we used the same tumor
tissue array as in Table 2, and performed IHC staining for
phospho-S2448 mTOR (Fig. 5E). Positive staining for phosphor-
ylated mTOR showed signiﬁcant correlation with positive
staining for GDF15 (Table 4). These data indicate that GDF15
expression is associated with mTOR activation in human ovarian
tumor tissues.
3.7. GDF15 pharmacologic inhibition or knockdown reduces growth
and invasion in an ovarian cancer model of endogenous GDF15 over-
expression
GDF15-speciﬁc ELISA showed that Tov21 ovarian cancer cells
secrete 33-fold higher levels of GDF15 compared to SKOv3 cells
(Fig. 6A). Treatment of Tov21 cells with GDF15 monoclonal
antibody (mAb) clone 147627 (R&D Systems) resulted in
neutralization of secreted GDF15 as compared to control IgG-
treated or untreated cells (Fig. 6B). GDF15 mAb also reduced
expression of MMP2, MMP9, and VEGF transcripts (Fig. 6C),
suppressed growth in matrigel (Fig. 6D), and blocked invasive-
ness (Fig. 6E) of Tov21 cells compared to control IgG-treated
cells.
Real-time PCR indicated that endogenous expression of the
GDF15 transcript was increased in Tov21 by approximately 7-
fold relative to SKOv3 cells (Fig. 7A). GDF15 expression was
knocked down using lentiviral GDF15 shRNA (Fig. 7B), which
also resulted in reduced expression of MMP2, MMP9, and VEGF
transcripts (Fig. 7C). GDF15 knockdown reduced growth in
matrigel (Fig. 7D) and invasiveness (Fig. 7E) of Tov21 cells
relative to control shRNA-infected cells. Knockdown of GDF15
reduced the ratio of phosphorylated to total 4EBP1 and p38,
with a slight reduction in phosphorylated to total Erk1/2 also
observed (Fig. 7F). In contrast, phosphorylation of Akt was not
reduced. These results suggest that GDF15 knockdown reduces
mTOR and MAPK signaling and suppresses growth and invasion
of Tov21 ovarian cancer cells. The lack of effect on Akt
phosphorylation as well as the modest effect on Erk1/2 may
have been due to our ability to achieve only a partial knockdown
(Fig. 7B). Future studies will attempt to develop knockdown
strategies that achieve greater suppression of GDF15, and will
then determine if PI3K and MAPK signaling are reduced to a
greater extent when expression of endogenous GDF15 is more
completely blocked.
Fig. 4. PI3K/mTORc1 and MAPK signaling are activated by GDF15 in ovarian cancer cells. (A) SKOv3 cells were serum starved overnight, and then stimulated with 20 ng/mL
rhGDF15 for 2 or 5 min, or with the corresponding volume of vehicle control for 5 min. Western blots of total protein lysates were performed at least 3 times for p-Thr180/
Tyr182 p38MAPK, total p38, p-Thr202/Tyr204 p42/p44 Erk1/2, total Erk1/2, p-S473 Akt, and total Akt; representative blots are shown. Quantiﬁcation is shown as a ratio of
phospho-protein to total protein, and is shown relative to vehicle control. (B) SKOv3 cells were plated in matrigel. Cells were maintained in media containing vehicle control,
20 ng/mL rhGDF15, or GDF15 plus 1 mM PI3K inhibitor LY294002, 100 nM MEK inhibitor PD0325901, or 10 mM p38MAPK inhibitor SB203580. Media and drugs were changed
twice a week for 3–4 weeks. Matrigel was dissolved using dispase and cells were counted by trypan blue exclusion. Fold change in anchorage-independent (AI) growth is
shown relative to the vehicle control group; **p < 0.005 for GDF15-stimulated versus control vehicle, and for inhibitor + GDF15 groups versus GDF15 alone. (C) Total protein
lysates from SKOv3 stable control and GDF15 clones 1, 3, and 5 were Western blotted at least twice for phosphorylated and total p38MAPK, Akt, and 4EBP1; representative
blots are shown. Quantiﬁcation is shown as a ratio of phosphorylated to total protein, and is shown relative to control clone. (D) (Left) GDF15 stable clone 1 (G1) and clone 3
(G3) and control empty vector clone cells were treated with 10 nM or 100 nM of rapamycin, or with (right) 1, 5, or 10 mM TGF beta receptor type II inhibitor SB431542. Control
groups (C) were treated with DMSO alone. After 72 h, MTS proliferation assays were performed. Proliferation is shown as a percentage of the control vehicle group per cell line,
and reﬂects the average of six replicates. (E) SKOv3 cells were plated in matrigel. Cells were maintained in media containing vehicle control, 20 ng/mL GDF15, or GDF15 plus
100 nM rapamycin or 5 mM TGF beta receptor type II inhibitor SB431542. Media and drugs were changed twice a week for 3–4 weeks. Matrigel was dissolved using dispase
and cells were counted by trypan blue exclusion. Fold change in anchorage-independent (AI) growth is shown relative to the control group. (F) GDF15 stable clone 1 (G1) and
clone 3 (G3) and control empty vector clone cells were treated with DMSO control (C) and the concentrations shown for LY294002, PD0325901, or SB203580. After 72 h, MTS
proliferation assays were performed. Proliferation is shown as a percentage of the control vehicle group per cell line, and reﬂects the average of six replicates.
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Ovarian cancer is the leading cause of death from gynecologic
tumors in the United States. Approximately 22,000 women will be
diagnosed with ovarian cancer this year, with 15,000 dying fromthe disease [17]. Most cases are diagnosed at a late stage, and
generally carry a poor prognosis as they have already spread
outside of the ovary. Identiﬁcation of a biomarker for ovarian
cancer may facilitate diagnosis at an earlier stage, and could
provide a new molecular target for blocking metastatic spread.
Fig. 5. Rapamycin inhibits GDF15-mediated ovarian cancer cell invasion. (A) SKOv3 cells were plated in Boyden invasion chambers in the presence of vehicle control, 20 ng/
mL GDF15, or GDF15 plus 100 nM rapamycin (Rp). Photos were taken after 24 h of invasion (representatives shown), and the number of invaded cells was counted in ten
different ﬁelds per sample. Values reﬂect the total number of invaded cells in triplicate cultures per group. (B) SKOv3 cells were treated with vehicle control, 20 ng/mL GDF15,
or 20 ng/mL GDF15 plus 100 nM rapamycin (Rp). Real-time PCR was performed for MMP-9 and VEGF. Values reﬂect the fold change in transcript normalized to RPLPO
housekeeping gene. (C) SKOv3 GDF stable clones 1 and 3 were plated in Boyden invasion chambers in the presence of vehicle control (C) or 100 nM rapamycin (Rp). After 24 h
of invasion, the number of invaded cells was counted in ten different ﬁelds per sample. Values reﬂect the total number of invaded cells in triplicate cultures per group. (D)
SKOv3, SKOv3 stable control clone, GDF15 stable clone 1, and GDF15 stable clone 3 were plated in the presence of 5% FBS, and 100 nM rapamycin (Rp) where indicated, in the
upper chamber of XCelligence CIM-plates. Medium containing 10% FBS, and 20 ng/mL rhGDF15 (G) where indicated, was placed into the plate’s corresponding bottom
chambers. CIM-plates were monitored every 15 min for 10 h. Standardized cell index (CI) values were plotted linearly against time. The CI slope per hour was calculated and is
shown here as a measure of migration. Values reﬂect the average of triplicates at each time point.
S.E. Griner et al. / Biochemical Pharmacology 85 (2013) 46–5854In the current study, we show that the cytokine GDF15 was
expressed at high levels in 70–80% of all ovarian tumors.
Approximately 96% of serous tumors, the most common subtype
of ovarian cancer, showed elevated GDF15 expression. Bock et al.
[7] previously reported that 97% (111 of 114) of ovarian tumorsshowed cytoplasmic staining for GDF15. In that study, high GDF15
staining correlated with reduced overall survival. Similarly, Staff
et al. [4] reported that high plasma GDF15 levels were an
independent predictor of reduced overall survival. GDF15 has been
suggested to be a biomarker for several cancer types including
Table 4
IHC analysis of p-S2448 mTOR and correlation with GDF15 expression.
GDF15 p-mTOR
Neg (1.0) Pos (>1.0)
N % N %
Negative (1.0) (n = 33) 17 51.5 16 48.5
Positive (>1.0) (n = 106) 33 31.1 73 68.9
89 of 139 (64%) of ovarian tumor tissues showed positive staining for p-S2448
mTOR. GDF15 and phosphorylation of mTOR were signiﬁcantly correlated
(p = 0.0393, Fisher’s exact).
S.E. Griner et al. / Biochemical Pharmacology 85 (2013) 46–58 55pancreatic, prostate, colorectal, and multiple myeloma [1–3,5,18].
Our ﬁndings together with those previously reported suggest that
GDF15 should be studied further as a potential biomarker of
ovarian cancer progression.Fig. 6. Neutralization of secreted GDF15 reduces invasion and growth of GDF15-overexp
by ELISA in media from SKOv3 and Tov21 cell lines. Cells were incubated in serum-fre
samples per group. (B) Tov21 cells were either untreated, or treated with 1 mg/mL contro
media was measured by ELISA in triplicates per group. Values reﬂect the average fold exp
mAb for 24 h. Real-time PCR was then performed for MMP-2, MMP-9, and VEGF, and norm
Tov21 cells were plated in matrigel and treated with 1 mg/mL control IgG or GDF15 mAb
using dispase and cells were counted by trypan blue exclusion. The percentage of anchor
were plated in Boyden chambers and treated with 1 mg/mL control IgG or GDF15 mAb (14
sample. Values reﬂect the total number of invaded cells in triplicate cultures per grouStimulation of ovarian cancer cells with exogenous GDF15 or
stable transfection with a GDF15 expression plasmid induced
growth and invasion through matrigel. GDF15 caused an increased
expression of MMPs, which mediate basement membrane
breakdown and invasion. Our results showed that greater than
85% of all of the ovarian tumor tissues stained positive for MMP2
and MMP9, including more than half of the GDF15-negative
samples (Table 3). These results suggest that elevated MMP2 and
MMP9 may be a general ﬁnding amongst ovarian cancer tissues. In
fact, levels of MMP2 and MMP9 have previously been reported to
be increased in a majority of patients with ovarian cancer
[14,19,20]. Our IHC analysis indicated a signiﬁcant correlation
between GDF15 expression and MMP2 and MMP9 positivity in
human ovarian tumors. In addition, pharmacologic MMP inhibi-
tion suppressed GDF15-mediated invasion, conﬁrming that
GDF15-driven invasion is likely to be MMP-dependent. MMP2ressing ovarian cancer cells. (A) Concentrations of secreted GDF15 were determined
e media for 48 h prior to ELISA. Values reﬂect the average fold expression in three
l IgG or GDF15 mAb (147627; R&D Systems) for 24 h. The concentration of GDF15 in
ression per group. (C) Tov21 cells were treated with 1 mg/mL control IgG or GDF15
alized to RPLPO. Values reﬂect the average fold change in normalized transcript. (D)
 (147627); media was changed twice a week for 3–4 weeks. Matrigel was dissolved
age-independent (AI) growth is shown relative to the control group. (E) Tov21 cells
7627). After 24 h, the number of invaded cells was counted in ten different ﬁelds per
p.
Fig. 7. GDF15 knockdown reduces invasion and growth in association with reduced p-4EBP1 in GDF15-overexpressing ovarian cancer cells. (A) Real-time PCR was performed
for GDF15 in SKOv3 and Tov21 cells, and normalized to the level of internal control transcript RPLPO. Values reﬂect the average fold change in normalized GDF15 transcript.
(B) Tov21 cells were infected with lentiviral GDF15 shRNA or control shRNA. Real-time PCR was then performed for GDF15 and RPLPO. Values reﬂect the average fold change
in normalized GDF15 transcript. (C) Tov21 cells were infected with lentiviral GDF15 shRNA or control shRNA. Real-time PCR was performed for MMP-2, MMP-9, and VEGF,
and normalized to RPLPO. Values reﬂect the average fold change in normalized transcript. (D) Tov21 cells were plated in matrigel and infected with lentiviral control or GDF15
shRNA; media and virus were changed twice a week for 3–4 weeks. Matrigel was dissolved using dispase and cells were counted by trypan blue exclusion. The percentage of
anchorage-independent (AI) growth is shown. (E) Tov21 cells were plated in Boyden chambers and infected with control or GDF15 shRNA. After 24 h, the number of invaded
cells was counted in ten different ﬁelds per sample. Values reﬂect the total number of invaded cells in triplicate cultures per group. (F) Tov21 cells were infected with lentiviral
control shRNA or GDF15 shRNA for 48 h. Western blots were performed at least twice for phosphorylated and total 4EBP1, Erk1/2, p38, and Akt; representative blots are
shown. Quantiﬁcation is shown as a ratio of phosphorylated to total protein above each blot.
S.E. Griner et al. / Biochemical Pharmacology 85 (2013) 46–5856has been shown to be an early regulator of ovarian cancer
metastasis, with knockdown or pharmacologic inhibition of MMP2
reducing the number of metastases and tumor weight in an in vivo
model of ovarian cancer [21]. Thus, the ability of GDF15 to induceexpression of MMPs may be a critical downstream component of
its mechanism of invasion.
Several signaling pathways up-regulate expression of MMPs.
GDF15 activated PI3K/mTOR and MAPK signaling. Kinase
S.E. Griner et al. / Biochemical Pharmacology 85 (2013) 46–58 57inhibition of these pathways blocked GDF15-mediated growth of
ovarian cancer cells. However, proliferation of GDF15 stable
transfectants was dependent upon only mTOR signaling, as
rapamycin achieved dose-dependent inhibition of proliferation,
in contrast to PI3K and MEK inhibition. Rapamycin also suppressed
GDF15-mediated growth and invasion, and reduced GDF15-
stimulated expression of MMPs. Cancer cell motility and invasion
mediated by mTORc1-MMP signaling has been reported [22]. Our
results showed that pharmacologic mTORc1 inhibition completely
suppressed GDF15-mediated invasion and reduced MMP tran-
script levels, supporting the concept that mTOR signaling
contributes to GDF15-mediated invasion in ovarian cancer cells.
In addition, stable transfectants of GDF15 showed increased
phosphorylation of the mTORc1 substrate 4EBP1, while lentiviral
GDF15 shRNA suppressed phosphorylation of 4EBP1 in Tov21 cells.
In contrast to GDF15 stimulation in SKOv3 and CaOv3 cells, GDF15
knockdown did not appear to affect Akt and had a modest effect on
Erk1/2 phosphorylation in Tov21 cells, suggesting that Tov21 cells
may not require GDF15 for sustained Akt or Erk1/2 signaling.
GDF15 showed robust stimulation of p38 phosphorylation, which
was reduced upon knockdown of GDF15 in Tov21 cells. Further
analysis is required to determine the contribution of p38 signaling
to GDF15-mediated growth and invasion, as well as the mecha-
nisms by which p38 is activated by GDF15. As suggested by our
data, genetically different cell lines are likely to display differential
signaling upon stimulation or knockdown of GDF15. However, the
same general signaling trend was observed in the various cell lines.
Our results suggest that GDF15-positive cells may be uniquely
dependent upon mTOR signaling versus other signaling pathways,
as rapamycin was able to inhibit proliferation, growth, and
invasion of GDF15-over-expressing cells. Activation of mTOR
signaling has previously been implicated in ovarian cancer
progression [8,9]. Several analogs of rapamycin are currently in
clinical development for treating multiple types of cancer. Based
on our results, there is rationale to investigate rapamycin analogs
in the context of GDF15-over-expressing ovarian cancer.
GDF15 is structurally similar to TGF beta, although a receptor
for GDF15 has not yet been identiﬁed. GDF15 appears to stimulate
phosphorylation of the TGF beta receptor substrate Smad2 [6].
However, pharmacologic inhibition of TGF beta receptor type II did
not reduce GDF15-mediated growth in ovarian cancer cells.
However, TGF beta receptor signaling is known to play an integral
role in EMT and cancer cell invasion. In fact, our preliminary data
showed that GDF15 stable clones adopt a mesenchymal morphol-
ogy and express elevated levels of the mesenchymal marker N-
cadherin. Thus, it is possible that GDF15 promotes an epithelial-to-
mesenchymal transition in ovarian cancer cells. Future studies will
examine the mechanisms by which GDF15 may mediate EMT and
invasion, including determining whether TGF beta receptor
signaling is involved in this process.
Amongst ovarian cancers that over-express GDF15, strategies
that block GDF15 signaling may prove to be beneﬁcial. We used
two strategies to inhibit GDF15: knockdown of endogenous GDF15
expression and neutralization of secreted GDF15. Both approaches
suppressed growth and invasion of GDF15-overexpressing ovarian
cancer cells. GDF15 knockdown reduced phosphorylation of
4EBP1, supporting the concept that mTORc1 signaling is a critical
component of the mechanism of GDF15-mediated growth and
invasion of ovarian cancer. Future studies will develop strategies
for improving knockdown of GDF15, including using nanoparticle-
conjugated knockdown approaches as we recently published [23]
to selectively target tumor cells. These strategies will be examined
for their ability to suppress invasion and progression of ovarian
cancer in cell culture and animal models.
Overall, our work supports investigation of GDF15 expression
or serum level as a potential predictor of ovarian cancerprogression. Having a reliable biomarker of disease is critical for
facilitating diagnosis of ovarian cancer at an earlier stage and
improving survival rates. Our studies suggest that patients with
GDF15-over-expressing ovarian cancer may derive beneﬁt from
rapamycin-based treatment. This work is of particular signiﬁcance
as it indicates that GDF15-mTOR signaling is a novel mechanism
driving ovarian cancer cell invasion, and that pharmacologically
targeting GDF15-mTOR signaling may ultimately block ovarian
tumor growth and invasion. GDF15-targeted approaches should be
studied further in pre-clinical animal models of ovarian cancer.
Further understanding of the mechanisms by which GDF15
stimulates mTOR signaling and promotes progression of ovarian
cancer may ultimately allow new therapeutic approaches to be
developed for patients with ovarian cancer.
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